List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7858679/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Current Status of Drug Discovery for the Oxytocin Receptor. Methods in Molecular Biology, 2022, 2384, 153-174.	0.4	3
2	TSPO PET Imaging as a Biomarker of Neuroinflammation in Neurodegenerative Disorders. Neuromethods, 2022, , 407-427.	0.2	2
3	Pharmacological characterization of a structural hybrid P2X7R antagonist using ATP and LL-37. European Journal of Pharmacology, 2022, 914, 174667.	1.7	5
4	The Isoxazole Derivative of Usnic Acid Induces an ER Stress Response in Breast Cancer Cells That Leads to Paraptosis-like Cell Death. International Journal of Molecular Sciences, 2022, 23, 1802.	1.8	14
5	Strategies for targeting the P2Y12 receptor in the central nervous system. Bioorganic and Medicinal Chemistry Letters, 2022, 71, 128837.	1.0	3
6	The discovery of a potent and selective pyrazolo-[2,3-e]-[1,2,4]-triazine cannabinoid type 2 receptor agonist. European Journal of Medicinal Chemistry, 2021, 210, 113087.	2.6	6
7	Global phosphoproteomics reveals DYRK1A regulates CDK1 activity in glioblastoma cells. Cell Death Discovery, 2021, 7, 81.	2.0	31
8	A binge high sucrose diet provokes systemic and cerebral inflammation in rats without inducing obesity. Scientific Reports, 2021, 11, 11252.	1.6	21
9	Tobramycin and Colistin display anti-inflammatory properties in CuFi-1 cystic fibrosis cell line. European Journal of Pharmacology, 2021, 902, 174098.	1.7	2
10	Prodromal neuroinflammatory, cholinergic and metabolite dysfunction detected by PET and MRS in the TgF344-AD transgenic rat model of AD: a collaborative multi-modal study. Theranostics, 2021, 11, 6644-6667.	4.6	42
11	Adventures in Translocation: Studies of the Translocator Protein (TSPO) 18 kDa*. Australian Journal of Chemistry, 2021, , .	0.5	1
12	O-GlcNAcylation of truncated NAC segment alters peptide-dependent effects on α-synuclein aggregation. Bioorganic Chemistry, 2020, 94, 103389.	2.0	10
13	Targeting the MAPK7/MMP9 axis for metastasis in primary bone cancer. Oncogene, 2020, 39, 5553-5569.	2.6	20
14	Tricyclic heterocycles display diverse sensitivity to the A147T TSPO polymorphism. European Journal of Medicinal Chemistry, 2020, 207, 112725.	2.6	4
15	PET imaging of P2X7R in the experimental autoimmune encephalomyelitis model of multiple sclerosis using [11C]SMW139. Journal of Neuroinflammation, 2020, 17, 300.	3.1	15
16	Rapid Antibacterial Activity of Cannabichromenic Acid against Methicillin-Resistant Staphylococcus aureus. Antibiotics, 2020, 9, 523.	1.5	12
17	Reversing binding sensitivity to A147T translocator protein. RSC Medicinal Chemistry, 2020, 11, 511-517.	1.7	4
18	Novel Furan-2-yl-1 <i>H</i> -pyrazoles Possess Inhibitory Activity against α-Synuclein Aggregation. ACS Chemical Neuroscience, 2020, 11, 2303-2315.	1.7	9

#	Article	IF	CITATIONS
19	Evaluation of ¹⁸ F-IAM6067 as a sigma-1 receptor PET tracer for neurodegeneration <i>in vivo</i> in rodents and in human tissue. Theranostics, 2020, 10, 7938-7955.	4.6	7
20	Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists. Science Signaling, 2020, 13, .	1.6	219
21	Cubanes in Medicinal Chemistry. Journal of Medicinal Chemistry, 2019, 62, 1078-1095.	2.9	97
22	An overview of late-stage functionalization in today's drug discovery. Expert Opinion on Drug Discovery, 2019, 14, 1137-1149.	2.5	140
23	First Nondiscriminating Translocator Protein Ligands Produced from a Carbazole Scaffold. Journal of Medicinal Chemistry, 2019, 62, 8235-8248.	2.9	13
24	Strategies to develop selective CB2 receptor agonists from indole carboxamide synthetic cannabinoids. European Journal of Medicinal Chemistry, 2019, 180, 291-309.	2.6	19
25	Recent Developments in TSPO PET Imaging as A Biomarker of Neuroinflammation in Neurodegenerative Disorders. International Journal of Molecular Sciences, 2019, 20, 3161.	1.8	173
26	Synthesis of Usnic Acid Derivatives and Evaluation of Their Antiproliferative Activity against Cancer Cells. Journal of Natural Products, 2019, 82, 1768-1778.	1.5	27
27	Challenges and Opportunities in Central Nervous System Drug Discovery. Trends in Chemistry, 2019, 1, 612-624.	4.4	46
28	<i>O</i> -GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease. ACS Chemical Neuroscience, 2019, 10, 2209-2221.	1.7	56
29	Radiosynthesis of (<i>R</i> , <i>S</i>)â€{ ¹⁸ F]GE387: A Potential PET Radiotracer for Imaging Translocator Protein 18â€kDa (TSPO) with Low Binding Sensitivity to the Human Gene Polymorphism rs6971. ChemMedChem, 2019, 14, 982-993.	1.6	22
30	New-generation azaindole-adamantyl-derived synthetic cannabinoids. Forensic Toxicology, 2019, 37, 350-365.	1.4	11
31	Targeting the Oxytocin System: New Pharmacotherapeutic Approaches. Trends in Pharmacological Sciences, 2019, 40, 22-37.	4.0	43
32	The evolving science of phytocannabinoids. Nature Reviews Chemistry, 2018, 2, .	13.8	55
33	The role of polycyclic frameworks in modulating P2X7 receptor function. Tetrahedron, 2018, 74, 1207-1219.	1.0	7
34	Conformationally rigid derivatives of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin-1a receptors. European Journal of Medicinal Chemistry, 2018, 143, 1644-1656.	2.6	6
35	Longitudinal investigation of neuroinflammation and metabolite profiles in the <scp>APP</scp> _{swe} ė <scp>PS</scp> 1 _{Δe9} transgenic mouse model of Alzheimer's disease. Journal of Neurochemistry, 2018, 144, 318-335.	2.1	26
36	In vivo assessment of neuroinflammation in progressive multiple sclerosis: a proof of concept study with [18F]DPA714 PET. Journal of Neuroinflammation, 2018, 15, 314.	3.1	64

TRISTAN A. REEKIE

#	Article	IF	CITATIONS
37	Imaging glial activation in patients with post-treatment Lyme disease symptoms: a pilot study using [11C]DPA-713 PET. Journal of Neuroinflammation, 2018, 15, 346.	3.1	46
38	Synthesis and in vitro evaluation of diverse heterocyclic diphenolic compounds as inhibitors of DYRK1A. Bioorganic and Medicinal Chemistry, 2018, 26, 5852-5869.	1.4	5
39	Peptides, Peptidomimetics, and Carbohydrate–Peptide Conjugates as Amyloidogenic Aggregation Inhibitors for Alzheimer's Disease. ACS Chemical Neuroscience, 2018, 9, 1530-1551.	1.7	70
40	Flexible Analogues of Azaindole DYRK1A Inhibitors Elicit Cytotoxicity in Glioblastoma Cells. Australian Journal of Chemistry, 2018, 71, 789.	0.5	6
41	Pharmacological exploration of peptide ligands with short residence-time at the oxytocin receptor. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-1-74.	0.0	Ο
42	Pyrazolo[1, 4]diazepine-based small molecule oxytocin receptor partial agonists. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-1-24.	0.0	0
43	The Polyphenol Altenusin Inhibits in Vitro Fibrillization of Tau and Reduces Induced Tau Pathology in Primary Neurons. ACS Chemical Neuroscience, 2017, 8, 743-751.	1.7	32
44	Structural Optimization and Pharmacological Evaluation of Inhibitors Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRK) and CDC-like kinases (CLK) in Glioblastoma. Journal of Medicinal Chemistry, 2017, 60, 2052-2070.	2.9	41
45	Porphyrin Donor and Tunable Push–Pull Acceptor Conjugates—Experimental Investigation of Marcus Theory. Chemistry - A European Journal, 2017, 23, 6357-6369.	1.7	21
46	Discovery and pharmacological evaluation of a novel series of adamantyl cyanoguanidines as P2X7 receptor antagonists. European Journal of Medicinal Chemistry, 2017, 130, 433-439.	2.6	24
47	Metal-acetylide addition to tetracyanoethylene. Tetrahedron Letters, 2017, 58, 2414-2416.	0.7	3
48	Ring-opened aminothienopyridazines as novel tau aggregation inhibitors. MedChemComm, 2017, 8, 1275-1282.	3.5	7
49	Investigation of pyrazolo-sulfonamides as putative small molecule oxytocin receptor agonists. European Journal of Medicinal Chemistry, 2017, 136, 330-333.	2.6	4
50	Synthesis and Pharmacological Profiling of the Metabolites of Synthetic Cannabinoid Drugs APICA, STS-135, ADB-PINACA, and 5F-ADB-PINACA. ACS Chemical Neuroscience, 2017, 8, 1673-1680.	1.7	42
51	Pharmacological evaluation of a novel series of urea, thiourea and guanidine derivatives as P2X 7 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2439-2442.	1.0	11
52	Rapid access to N-(indol-2-yl)amides and N-(indol-3-yl)amides as unexplored pharmacophores. Organic and Biomolecular Chemistry, 2017, 15, 576-580.	1.5	7
53	Pharmacological Evaluation of Novel Bioisosteres of an Adamantanyl Benzamide P2X ₇ Receptor Antagonist. ACS Chemical Neuroscience, 2017, 8, 2374-2380.	1.7	30
54	Determination and reduction of translocator protein (TSPO) ligand rs6971 discrimination. MedChemComm, 2017, 8, 202-210.	3.5	12

#	Article	IF	CITATIONS
55	Comparative Evaluation of Three TSPO PET Radiotracers in a LPS-Induced Model of Mild Neuroinflammation in Rats. Molecular Imaging and Biology, 2017, 19, 77-89.	1.3	58
56	Neuroimaging of translocator protein in patients with systemic lupus erythematosus: a pilot study using [¹¹ C]DPA-713 positron emission tomography. Lupus, 2017, 26, 170-178.	0.8	25
57	Pentaâ€2,4â€dienâ€1â€ones by Formal [3+2] Cycloaddition–Rearrangement of Electronâ€Deficient Diethyl 2â€(Dicyanomethylene)malonate with AlkÂynes. European Journal of Organic Chemistry, 2016, 2016, 716-724.	1.2	8
58	Detection of Neuroinflammation in a Rat Model of Subarachnoid Hemorrhage Using [18F]DPA-714 PET Imaging. Molecular Imaging, 2016, 15, 153601211663918.	0.7	15
59	A Three-Step Synthesis of Tetrasubstituted NH-Pyrroles. Organic Letters, 2016, 18, 2252-2255.	2.4	24
60	The Formation of Seven-Membered Heterocycles under Mild Pictet–Spengler Conditions: A Route to Pyrazolo[3,4]benzodiazepines. Journal of Organic Chemistry, 2016, 81, 4883-4889.	1.7	14
61	A systematic exploration of the effects of flexibility and basicity on sigma ($\ddot{l}f$) receptor binding in a series of substituted diamines. Organic and Biomolecular Chemistry, 2016, 14, 9388-9405.	1.5	2
62	Disinhibition-like behavior in a P301S mutant tau transgenic mouse model of frontotemporal dementia. Neuroscience Letters, 2016, 631, 24-29.	1.0	34
63	Pharmacology of Valinate and <i>tert</i> -Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues. ACS Chemical Neuroscience, 2016, 7, 1241-1254.	1.7	214
64	Push–pull chromophores by reaction of 2,3,5,6-tetrahalo-1,4-benzoquinones with 4-(N,N-dialkylanilino)acetylenes. Tetrahedron, 2016, 72, 1213-1224.	1.0	17
65	Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1 a receptors. European Journal of Medicinal Chemistry, 2016, 108, 730-740.	2.6	11
66	TSPO as a target for glioblastoma therapeutics. Biochemical Society Transactions, 2015, 43, 531-536.	1.6	24
67	Lack of neuroinflammation in the HIV-1 transgenic rat: an [18F]-DPA714 PET imaging study. Journal of Neuroinflammation, 2015, 12, 171.	3.1	21
68	Esterâ€Substituted Electronâ€Poor Alkenes for Cycloaddition–Retroelectrocyclization (CA–RE) and Related Reactions. European Journal of Organic Chemistry, 2015, 2015, 7264-7275.	1.2	14
69	New reactivity of 6,6-bis-donor-substituted pentafulvenes: one-step synthesis of highly substituted [3]cumulene and dihydropentalene. Tetrahedron, 2015, 71, 4393-4399.	1.0	13
70	Amyloid load and translocator protein 18ÂkDa in APPswePS1-dE9 mice: a longitudinal study. Neurobiology of Aging, 2015, 36, 1639-1652.	1.5	43
71	Recent Advances in the Development of Sigma-1 Receptor Ligands. Australian Journal of Chemistry, 2015, 68, 600.	0.5	7
72	Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. ACS Chemical Neuroscience, 2015, 6, 1546-1559.	1.7	202

TRISTAN A. REEKIE

#	Article	IF	CITATIONS
73	The [2 + 2] Cycloaddition–Retroelectrocyclization and [4 + 2] Hetero-Diels–Alder Reactions of 2-(Dicyanomethylene)indan-1,3-dione with Electron-Rich Alkynes: Influence of Lewis Acids on Reactivity. Organic Letters, 2015, 17, 3506-3509.	2.4	33
74	Two-photon absorption and spectroscopy of the lowest two-photon transition in small donor-acceptor–substituted organic molecules. Physical Review A, 2015, 91, .	1.0	20
75	Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. ACS Chemical Neuroscience, 2015, 6, 1445-1458.	1.7	167
76	Optimisation of LRRK2 inhibitors and assessment of functional efficacy in cell-based models of neuroinflammation. European Journal of Medicinal Chemistry, 2015, 95, 29-34.	2.6	31
77	WAY 267,464, a non-peptide oxytocin receptor agonist, impairs social recognition memory in rats through a vasopressin 1A receptor antagonist action. Psychopharmacology, 2015, 232, 2659-2667.	1.5	19
78	DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications. , 2015, 151, 87-98.		122
79	Structure–activity relationship studies of SEN12333 analogues: Determination of the optimal requirements for binding affinities at α7 nAChRs through incorporation of known structural motifs. European Journal of Medicinal Chemistry, 2015, 95, 277-301.	2.6	12
80	First Demonstration of Positive Allosteric-like Modulation at the Human Wild Type Translocator Protein (TSPO). Journal of Medicinal Chemistry, 2015, 58, 8743-8749.	2.9	12
81	Synthesis and Optoelectronic Properties of <i>Janus</i> -Dendrimer-Type Multivalent Donor–Acceptor Systems. Journal of Organic Chemistry, 2015, 80, 882-896.	1.7	43
82	Systematic Variation of Cyanobutaâ€1,3â€dienes and Expanded Tetracyanoquinodimethane Analogues as Electron Acceptors in Photoactive, Rigid Porphyrin Conjugates. European Journal of Organic Chemistry, 2015, 2015, 91-108.	1.2	14
83	Neuroinflammation and brain atrophy in former NFL players: An in vivo multimodal imaging pilot study. Neurobiology of Disease, 2015, 74, 58-65.	2.1	208
84	Strainâ€Accelerated Formation of Chiral, Optically Active Butaâ€1,3â€dienes. Angewandte Chemie - International Edition, 2015, 54, 349-354.	7.2	31
85	Extremely Efficient Two-Photon Absorption in Small Donor-Acceptor Substituted Organic Molecules. , 2015, , .		Ο
86	The translocator protein as a drug target in Alzheimer's disease. Expert Review of Neurotherapeutics, 2014, 14, 439-448.	1.4	20
87	Structure–activity relationships of N-substituted 4-(trifluoromethoxy)benzamidines with affinity for GluN2B-containing NMDA receptors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 828-830.	1.0	17
88	Regional brain distribution of translocator protein using [11C]DPA-713 PET in individuals infected with HIV. Journal of NeuroVirology, 2014, 20, 219-232.	1.0	78
89	Synthesis of Cyano‣ubstituted Diaryltetracenes from Tetraaryl[3]cumulenes. Angewandte Chemie - International Edition, 2014, 53, 4341-4345.	7.2	38
90	The First CNS-Active Carborane: A Novel P2X ₇ Receptor Antagonist with Antidepressant Activity. ACS Chemical Neuroscience, 2014, 5, 335-339.	1.7	118

#	Article	IF	CITATIONS
91	Body temperature and cardiac changes induced by peripherally administered oxytocin, vasopressin and the nonâ€peptide oxytocin receptor agonist <scp>WAY</scp> 267,464: a biotelemetry study in rats. British Journal of Pharmacology, 2014, 171, 2868-2887.	2.7	70
92	Pyrazolo[1,4]diazepines as non-peptidic probes of the oxytocin and vasopressin receptors. Tetrahedron Letters, 2014, 55, 4568-4571.	0.7	8
93	Investigations of amide bond variation and biaryl modification in analogues of α7 nAChR agonist SEN12333. European Journal of Medicinal Chemistry, 2014, 84, 200-205.	2.6	2
94	Could 18 F-DPA-714 PET imaging be interesting to use in the early post-stroke period?. EJNMMI Research, 2014, 4, 28.	1.1	40
95	RANEY® cobalt – an underutilised reagent for the selective cleavage of C–X and N–O bonds. Organic and Biomolecular Chemistry, 2014, 12, 7433-7444.	1.5	26
96	Intramolecular Cycloaddition Reactions of <i>cis</i> -1,2-Dihydrocatechol Derivatives Incorporating C3-Tethered Diazoketones, Nitrile Oxides, and Azides: Stereocontrolled Routes to Enantiomerically Pure Spiro[5.5]undecanes and Related Systems. Journal of Organic Chemistry, 2013, 78, 7100-7111.	1.7	6
97	A practical synthesis of (1S,4S)-2,5-diazabicyclo[2.2.1]heptane. Tetrahedron Letters, 2013, 54, 5345-5347.	0.7	9
98	Improved accessibility to the desoxy analogues of Δ9-tetrahydrocannabinol and cannabidiol. Tetrahedron Letters, 2013, 54, 52-54.	0.7	22
99	Acute Prosocial Effects of Oxytocin and Vasopressin When Given Alone or in Combination with 3,4-Methylenedioxymethamphetamine in Rats: Involvement of the V1A Receptor. Neuropsychopharmacology, 2013, 38, 2249-2259.	2.8	112
100	N-substituted 8-aminopentacyclo[5.4.0.02,6.03,10.05,9]undecanes as If receptor ligands with potential neuroprotective effects. Bioorganic and Medicinal Chemistry, 2013, 21, 6038-6052.	1.4	16
101	The Synthesis and Pharmacological Evaluation of Adamantane-Derived Indoles: Cannabimimetic Drugs of Abuse. ACS Chemical Neuroscience, 2013, 4, 1081-1092.	1.7	80
102	Synthesis of Biologically Active Seven-Membered-Ring Heterocycles. Synthesis, 2013, 45, 3211-3227.	1.2	30
103	Metabolism and Quantification of [¹⁸ F]DPA-714, a New TSPO Positron Emission Tomography Radioligand. Drug Metabolism and Disposition, 2013, 41, 122-131.	1.7	61
104	The development of radiotracers for imaging sigma (σ) receptors in the central nervous system (CNS) using positron emission tomography (PET). Journal of Labelled Compounds and Radiopharmaceuticals, 2013, 56, 215-224.	0.5	11
105	[18F]DPA-714: Direct Comparison with [11C]PK11195 in a Model of Cerebral Ischemia in Rats. PLoS ONE, 2013, 8, e56441.	1.1	77
106	The Therapeutic Potential of Sigma (σ) Receptors for the Treatment of Central Nervous System Diseases: Evaluation of the Evidence. Current Pharmaceutical Design, 2012, 18, 884-901.	0.9	39
107	A Raney-Cobalt-Mediated Tandem Reductive Cyclization Route to the 1,5-Methanoazocino[4,3- <i>b</i>]indole Framework of the Uleine and <i>Strychnos</i> Alkaloids. Journal of Organic Chemistry, 2012, 77, 10773-10781.	1.7	30
108	Initial evaluation in healthy humans of [18F]DPA-714, a potential PET biomarker for neuroinflammation. Nuclear Medicine and Biology, 2012, 39, 570-578.	0.3	115

#	Article	IF	CITATIONS
109	Exploration of ring size in a series of cyclic vicinal diamines with $lf1$ receptor affinity. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5493-5497.	1.0	11
110	Application of a Raney-Cobalt-Mediated Tandem Reductive Cyclization Protocol to Total Syntheses of the <i>Aspidosperma</i> Alkaloids (±)-Limaspermidine and (±)-1-Acetylaspidoalbidine. Organic Letters, 2012, 14, 5621-5623.	2.4	63
111	A Ïf 1 receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.02,6.03,10.05,9.08,11]dodecan-3-ols (AHDs). Bioorganic and Medicinal Chemistry Letters, 2012, 22, 6053-6058.	1.0	15
112	Synthesis and Biological Evaluation of Adenosines with Heterobicyclic and Polycyclic <i>N</i> ⁶ ‣ubstituents as Adenosine A ₁ Receptor Agonists. ChemMedChem, 2012, 7, 1191-1201.	1.6	5
113	Consequences of linker length alteration of the α7 nicotinic acetylcholine receptor (nAChR) agonist, SEN12333. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 2380-2384.	1.0	7
114	A practical, multigram synthesis of the 2-(2-(4-alkoxyphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide (DPA) class of high affinity translocator protein (TSPO) ligands. Tetrahedron Letters, 2012, 53, 3780-3783.	0.7	11
115	N-Arylalkyl-2-azaadamantanes as cage-expanded polycarbocyclic sigma ($ f $ receptor ligands. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5289-5292.	1.0	21
116	Effects of linker elongation in a series of N-(2-benzofuranylmethyl)-N′-(methoxyphenylalkyl)piperazine σ1 receptor ligands. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5707-5710.	1.0	7
117	Reduced PBR/TSPO Expression After Minocycline Treatment in a Rat Model of Focal Cerebral Ischemia: A PET Study Using [18F]DPA-714. Molecular Imaging and Biology, 2011, 13, 10-15.	1.3	63
118	Trishomocubane as a scaffold for the development of selective dopamine transporter (DAT) ligands. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 38-41.	1.0	17
119	Molecular hybridization of 4-azahexacyclo[5.4.1.02,6.03,10.05,9.08,11]dodecane-3-ol with sigma (σ) receptor ligands modulates off-target activity and subtype selectivity. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 3622-3626.	1.0	13
120	Oxo-bridged isomers of aza-trishomocubane sigma (lf) receptor ligands: Synthesis, in vitro binding, and molecular modeling. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 145-148.	1.0	27
121	Pyrazolo[1,5-a]pyrimidine acetamides: 4-Phenyl alkyl ether derivatives as potent ligands for the 18kDa translocator protein (TSPO). Bioorganic and Medicinal Chemistry Letters, 2010, 20, 5799-5802.	1.0	35
122	Evaluation of the PBR/TSPO Radioligand [¹⁸ F]DPA-714 in a Rat Model of Focal Cerebral Ischemia. Journal of Cerebral Blood Flow and Metabolism, 2010, 30, 230-241.	2.4	184
123	Development of Vesicular Acetylcholine Transporter Ligands: Molecular Probes for Alzheimers Disease. Current Bioactive Compounds, 2010, 6, 129-155.	0.2	5
124	Design, Synthesis, and Structureâ^'Affinity Relationships of Regioisomeric <i>N</i> -Benzyl Alkyl Ether Piperazine Derivatives as Ïf-1 Receptor Ligands. Journal of Medicinal Chemistry, 2010, 53, 6228-6239.	2.9	62
125	Fluorine-18 Chemistry for PET: A Concise Introduction. Current Radiopharmaceuticals, 2010, 3, 68-80.	0.3	36
126	Initial Evaluation of ¹¹ C-DPA-713, a Novel TSPO PET Ligand, in Humans. Journal of Nuclear Medicine, 2009, 50, 1276-1282.	2.8	117

#	Article	IF	CITATIONS
127	Comparative Evaluation of the Translocator Protein Radioligands ¹¹ C-DPA-713, ¹⁸ F-DPA-714, and ¹¹ C-PK11195 in a Rat Model of Acute Neuroinflammation. Journal of Nuclear Medicine, 2009, 50, 468-476.	2.8	208
128	[11C]-DPA-713 and [18F]-DPA-714 as New PET Tracers for TSPO: A Comparison with [11C]-(R)-PK11195 in a Rat Model of Herpes Encephalitis. Molecular Imaging and Biology, 2009, 11, 386-98.	1.3	113
129	Challenges in molecular imaging of Parkinson's disease: A brief overview. Brain Research Bulletin, 2009, 78, 105-108.	1.4	7
130	Cubyl amides: Novel P2X7 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 3720-3723.	1.0	34
131	DPA-714, a New Translocator Protein–Specific Ligand: Synthesis, Radiofluorination, and Pharmacologic Characterization. Journal of Nuclear Medicine, 2008, 49, 814-822.	2.8	237
132	The Chemoenzymatic Total Synthesis of Phellodonic Acid, a Biologically Active and Highly Functionalized Hirsutane Derivative Isolated from the Tasmanian Fungus Phellodon melaleucus. Australian Journal of Chemistry, 2008, 61, 94.	0.5	30
133	11C-DPA-713: A Novel Peripheral Benzodiazepine Receptor PET Ligand for In Vivo Imaging of Neuroinflammation. Journal of Nuclear Medicine, 2007, 48, 573-581.	2.8	137
134	Positron emission tomography imaging of neuroinflammation. Neurotherapeutics, 2007, 4, 443-452.	2.1	119
135	Trishomocubanes: Novel σ ligands modulate cocaine-induced behavioural effects. European Journal of Pharmacology, 2007, 555, 37-42.	1.7	25